Literature DB >> 27785605

Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.

Ilja Spellmann1,2, Rebecca Schennach3,4, Florian Seemüller3,5, Sebastian Meyer3,6, Richard Musil3, Markus Jäger7, Max Schmauß8, Gerd Laux9, Herbert Pfeiffer10, Dieter Naber11, Lutz G Schmidt12, Wolfgang Gaebel13, Joachim Klosterkötter14, Isabella Heuser15, Michael Bauer16, Mazda Adli17, Joachim Zeiler18, Wolfram Bender10, Klaus-Thomas Kronmüller19, Marcus Ising20, Peter Brieger21, Wolfgang Maier22, Matthias R Lemke23, Eckart Rüther3, Stefan Klingberg24, Markus Gastpar17, Michael Riedel3,25, Hans-Jürgen Möller3.   

Abstract

The objective of the present study was the application and comparison of common remission and recovery criteria between patients with the diagnosis of schizophrenia and major depressive disorder (MDD) under inclusion of other outcome parameters. Patients with schizophrenia and MDD who were treated as inpatients at the beginning of the study were examined within two naturalistic follow-up trials from admission to discharge of an inpatient treatment period and the one-year follow-up assessment. PANSS criteria of the Remission in Schizophrenia Working Group (RSWG) for schizophrenia and HAMD criteria of the ACNP Task Force in MDD for depressive patients as well as the Clinical Global Impression-Severity Scale (CGI-S) were applied as symptomatic outcome measures additionally to functional outcome parameters. Data of 153 schizophrenia patients and 231 patients with a MDD episode have been included in the analysis. More depressive than schizophrenia patients reached a threshold score of ≤3 on the CGI-S, indicating symptomatic remission at discharge and at the one-year follow-up. In contrast similar proportions of patients reaching symptomatic remission at discharge from inpatient treatment and at the one-year follow-up in the schizophrenia and in the MDD group were found when disease-related consensus criteria (RSWG vs. ACNP Task Force) were used. Functional remission and recovery rates were significantly lower in schizophrenia than in depressive patients at the one-year follow-up visit. Common outcome criteria for remission and recovery in schizophrenia and major depression were not directly comparable. However, our results indicated a significantly poorer outcome in schizophrenia than in depressive patients according to terms of remission and recovery.

Entities:  

Keywords:  Major depression; Outcome criteria; Recovery; Remission; Schizophrenia

Mesh:

Year:  2016        PMID: 27785605     DOI: 10.1007/s00406-016-0741-2

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  41 in total

1.  A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.

Authors:  R Schennach-Wolff; H-J Möller; M Jäger; F Seemüller; M Obermeier; T Messer; G Laux; H Pfeiffer; D Naber; L G Schmidt; W Gaebel; J Klosterkötter; I Heuser; W Maier; M R Lemke; E Rüther; S Klingberg; M Gastpar; M Riedel
Journal:  Pharmacopsychiatry       Date:  2010-10-06       Impact factor: 5.788

2.  Comparison of long-term outcome of schizophrenic, affective and schizoaffective disorders.

Authors:  A Marneros; A Deister; A Rohde
Journal:  Br J Psychiatry Suppl       Date:  1992-10

3.  Recovery from schizophrenia: a concept in search of research.

Authors:  Robert Paul Liberman; Alex Kopelowicz
Journal:  Psychiatr Serv       Date:  2005-06       Impact factor: 3.084

4.  A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.

Authors:  Gopalan Sethuraman; Cindy C Taylor; Mark Enerson; Eduardo Dunayevich
Journal:  Schizophr Res       Date:  2005-07-28       Impact factor: 4.939

5.  Identification of loci associated with schizophrenia by genome-wide association and follow-up.

Authors:  Michael C O'Donovan; Nicholas Craddock; Nadine Norton; Hywel Williams; Timothy Peirce; Valentina Moskvina; Ivan Nikolov; Marian Hamshere; Liam Carroll; Lyudmila Georgieva; Sarah Dwyer; Peter Holmans; Jonathan L Marchini; Chris C A Spencer; Bryan Howie; Hin-Tak Leung; Annette M Hartmann; Hans-Jürgen Möller; Derek W Morris; Yongyong Shi; GuoYin Feng; Per Hoffmann; Peter Propping; Catalina Vasilescu; Wolfgang Maier; Marcella Rietschel; Stanley Zammit; Johannes Schumacher; Emma M Quinn; Thomas G Schulze; Nigel M Williams; Ina Giegling; Nakao Iwata; Masashi Ikeda; Ariel Darvasi; Sagiv Shifman; Lin He; Jubao Duan; Alan R Sanders; Douglas F Levinson; Pablo V Gejman; Sven Cichon; Markus M Nöthen; Michael Gill; Aiden Corvin; Dan Rujescu; George Kirov; Michael J Owen; Nancy G Buccola; Bryan J Mowry; Robert Freedman; Farooq Amin; Donald W Black; Jeremy M Silverman; William F Byerley; C Robert Cloninger
Journal:  Nat Genet       Date:  2008-09       Impact factor: 38.330

6.  Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application.

Authors:  Stefan Leucht
Journal:  J Clin Psychiatry       Date:  2014       Impact factor: 4.384

7.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

8.  DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 1: general aspects and paradigmatic discussion of depressive disorders.

Authors:  Hans-Jürgen Möller; Borwin Bandelow; Michael Bauer; Harald Hampel; Sabine C Herpertz; Michael Soyka; Utako B Barnikol; Simone Lista; Emanuel Severus; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-14       Impact factor: 5.270

9.  Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.

Authors:  Jeffrey A Lieberman; Michael Phillips; Hongbin Gu; Scott Stroup; Peiyan Zhang; Lan Kong; Zhongfu Ji; Gary Koch; Robert M Hamer
Journal:  Neuropsychopharmacology       Date:  2003-03-26       Impact factor: 7.853

Review 10.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

View more
  2 in total

1.  Reduced habenular volumes and neuron numbers in male heroin addicts: a post-mortem study.

Authors:  Hans-Gert Bernstein; Johann Steiner; Ulf J Müller; Moritz Ahrens; Veronika Vasilevska; Henrik Dobrowolny; Kolja Schiltz; Konstantin Schlaaff; Christian Mawrin; Thomas Frodl; Bernhard Bogerts; Tomasz Gos; Kurt Truebner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-10-01       Impact factor: 5.270

Review 2.  Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis.

Authors:  Ana Catalan; Anja Richter; Gonzalo Salazar de Pablo; Julio Vaquerizo-Serrano; Gonzalo Mancebo; Borja Pedruzo; Claudia Aymerich; Marco Solmi; Miguel Á González-Torres; Patxi Gil; Philip McGuire; Paolo Fusar-Poli
Journal:  Eur Psychiatry       Date:  2021-11-03       Impact factor: 5.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.